Dermatological Adverse Reactions and Therapeutic Potential of Semaglutide, Liraglutide, and Tirzepatide: Analysis of UK Pharmacovigilance Data and Literature Review
August 2025
TLDR GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.
GLP-1 receptor agonists (GLP-1RAs), including semaglutide, liraglutide, and tirzepatide, are recognized for their metabolic benefits and complex dermatological profiles. They show significant potential in improving psoriasis and hidradenitis suppurativa due to their anti-inflammatory and immunomodulatory properties. However, they are also linked to adverse dermatological effects, such as alopecia, with tirzepatide having the highest reports of alopecia (140 cases) compared to semaglutide (91) and liraglutide (18). The UK MHRA reported 1,369 dermatological cases by May 2025, and US data indicates a 186% increase in dermatological event reporting from 2022-2023. Dermatologists must weigh these therapeutic benefits against safety concerns, emphasizing proactive monitoring and patient counselling as GLP-1RAs are increasingly used beyond diabetes treatment.